Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELT-100 bioavailability study
NCT04485702Phase 1Completed
- Sponsor
- Melt Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of midazolam + ketamine in Procedural sedation (PS) (3 arms), sponsored by Melt Pharmaceuticals. Primary endpoints: Peak Plasma Concentration at 24 hours, Area under the plasma concentration versus time curve at 24 hours and 1 more. Started Jul 2020; status: completed.
02
Drugs
midazolam + ketamine
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT04485702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485702.